Archive for the ‘Health Care Stocks’ Category

« Older Entries
Newer Entries »

M&A activity for small and mid-cap biotechs could pick up in 2010, JP Morgan analyst says

Wednesday, June 2nd, 2010

Earlier this year, J.P. Morgan’s senior biotech analyst, Geoff Meacham gave his macro view of the biotech industry. “M&A activity for small and mid-cap biotech may pick up, driven by Pharma but also driven by large cap biotechs,” he said. “In this report, we’ve stressed pipelines and sustainability of growth, but as growth in the large cap group matures, increased cash flow generation may fuel increased M&A activity.”

A few notable names with “high strategic values” included: Acorda Therapeutics, Inc. (Nasdaq: ACOR), AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP), Medivation, Inc. (Nasdaq: MDVN), United Therapeutics Corp. (Nasdaq: UTHR), Vertex Pharmaceuticals, Inc. (Nasdaq: VRTX), Human Genome Sciences, Inc. (Nasdaq: HGSI), Seattle Genetics, Inc. (Nasdaq: SGEN) and Savient Pharmaceuticals, Inc. (Nasdaq: SVNT).”

Lehman bullish on small, mid-caps, too:

“Opportunities for the U.S. biotechnology group are selective and we tend to prefer small-mid cap stocks over large-cap stocks overall in 1H10,” said Lehman Brothers analyst, Jim Birchenough. “Within the large cap group our rank order of preference is Amgen, Genzyme and Celgene as top picks with Gilead and Biogen Idec viewed less favorably. Top mid-cap picks include Amylin Pharmaceuticals (Nasdaq: AMLN), Cephalon (Nasdaq: CEPH), Human Genome Sciences (Nasdaq: HGSI), Onyx Pharmaceuticals (Nasdaq: ONXX) and Regeneron Pharmaceuticals(Nasdaq: REGN) while we are less positive on Theravance (Nasdaq: THRX), OSI Pharmaceuticals (Nasdaq: OSIP) and Zymogenetics(Nasdaq: ZGEN).

Biotech Buzz Stocks for 2010:

Here are a few of our favorite small and mid cap biotech Buzz Stocks for 2010:  Akorn, Inc. (Nasdaq: AKRX), Neurocrine Biosciences, Inc. (Nasdaq: NBIX), Metabolix, Inc. (Nasdaq: MBLX), and Raptor Pharmaceuticals Corp.

Let us know your top biotech picks!

Tags: , , , , , , , , , , , , , , , , ,
Posted in Health Care Stocks, Penny Stocks | No Comments »

Penny Buzz Stocks to Watch – ENMD, IMUC, OOAG

Wednesday, June 2nd, 2010

Here are a few penny stocks on our radar today and why:

Entremed, Inc. (Nasdaq: ENMD): announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. ENMD-2076 demonstrated robust antitumor activity against murine xenograft models of human colorectal cancer (CRC) established from both cell lines and primary human samples.

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC): Announced positive results from a Phase I study of the company’s immune-based cancer therapy, ICT-107.

OMDA Oil and Gas, Inc. (Pink Sheets: OOAG): Announced a reduction of 12,000,000 common shares which is 5 percent of the total outstanding share count. Upon the completion of all of the announced share retirements the new outstanding share count will stand at 172,610,100. In total OMDA Oil and Gas, Inc. will have reduced its outstanding share total nearly 30% from the original 242,610,100. Upon completion of all pending share cancellations OMDA’s insiders will collectively hold less than 10% of the common vote.

Sign up for our Buzz Stock alerts via e-mail and get our Buzz Stocks first!

Tags: , , ,
Posted in Health Care Stocks, Materials Stocks, Penny Stocks | No Comments »

Neurocrine Biosciences, Inc. (NBIX) – Buzz Stock of the Day

Tuesday, May 25th, 2010

Shares of drug developer, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) were up 54 percent in morning trading on Tuesday, after the company announced “statistically significant and clinically meaningful” top-line efficacy results from its Daisy PETAL phase II study of elagolix, a treatment for patients with endometriosis.

The San Diego-based company said the drug, elagolix, showed statistically significant reductions in pelvic pain during menstruation, and non-menstrual pelvic pain and dyspareunia, or painful intercourse, when compared to placebo. The US based Daisy PETAL study enrolled 137 endometriosis subjects into one of two treatment groups; elagolix 150 mg or placebo once daily for two months of treatment, in a double-blind design. Subjects are continuing for four months of open-label elagolix treatment and assessments. These top-line efficacy results are based on the ITT population of 132 women.

[–quote–]

Shares began rallying in after-hours trading on Monday, after the company issued its announcement.

“The Daisy PETAL study was successful, all primary and secondary efficacy endpoints were met, and provided exactly the information we need to move this program forward,” said Chris O’Brien, M.D., Chief Medical Officer at Neurocrine in a statement. “We now have confirmation that the daily scales for menstrual and non-menstrual pelvic pain, developed with extensive input from the FDA and patients, function well in a clinical trial setting. These daily endpoints reflect the way women with endometriosis experience their symptoms and also demonstrate improvement with elagolix.”

Shares of NBIX have been up as much as 58 percent in the past three months.

Tags: , , ,
Posted in Health Care Stocks | 3 Comments »

Vasomedical, Inc. (VASO) – Penny Stock of the Day

Monday, May 24th, 2010

Shares of Vasomedical, Inc. (OTCBB: VASO) were up as much as 86 percent on Monday after the company announced that its subsidiary was appointed the exclusive representative for select GE Healthcare Diagnostic Imaging products to specific market segments in the 48 contiguous states of the United States and District of Columbia received signed a sales representative agreement. GE Healthcare is the healthcare business unit of GE (NYSE: GE – News). The Company has already received financial commitments for up to $5 million to fund this project.

[–quote–]

“This representation agreement is an example of Vasomedical’s strategy to expand its operations into new areas of potential growth in healthcare,” stated Abraham E. Cohen, Chairman of the Board of Vasomedical, Inc. in a statement.

The agreement is for an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances.

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP(R) external counterpulsation systems based on the Company’s proprietary technology. Offered exclusively by Vasomedical, EECP therapy is a safe, non-invasive, outpatient treatment option for patients suffering from ischemic heart diseases such as angina and heart failure

In early April, the company announced that it received clearance from the U.S. Food and Drug Administration to market its Vasomedical-BIOX™ Model 2301 Combined ECG Holter and Ambulatory Blood Pressure Monitoring Recorder and Software Analysis System.

“These are the first in a line of Vasomedical-BIOX™ ECG Holter and Ambulatory Blood Pressure Monitoring Systems that Vasomedical intends to bring to the marketplace,” said Dr. Jun Ma, President and CEO of Vasomedical, Inc.

Shares of Vasomedical are up more than 300 percent over the past 12 months.

Tags: , , , , , ,
Posted in Health Care Stocks, Penny Stocks, Technology Stocks | No Comments »

Metabolix, Inc. (MBLX) – Buzz Stock of the Day

Wednesday, May 12th, 2010

Shares of bioplastics developer, Metabolix, Inc. (Nasdaq: MBLX) surged as much as 18 percent in morning trading on Wednesday after the company announced the U.S. Food and Drug Administration approved its plastics products Mirel F1005 and F1006 for use in food contact applications.

[–quote–]

“With the Clinton plant now in operation, and this FDA clearance, we now can move forward with brand owners’ requests to use Mirel in their injection molded food packaging applications,” said Richard Eno, CEO of Metabolix in a statement. “These applications, which currently consume billions of pounds of petroleum-based polymers per year, offer considerable opportunity for growth of our biobased, biodegradable polymer, Mirel.”

Metabolix shares are up 54 percent over the past three months

Tags: , , ,
Posted in Health Care Stocks | 1 Comment »

« Older Entries
Newer Entries »